Published online 2023 February 25.

Letter

Is a New Post-infectious Inflammatory Phenomenon Emerging? Increasing Evidence of a New Multiple Organ Involvement Syndrome in Children

Mehrnaz Olfat ^{[1,2}, Seyed Hossein Mirlohi^{3,2}, Meisam Sharifzadeh ^{[1,2} and Masoud Mohammadpour ^{[1,4,*}

¹Children's Medical Center, Pediatric Center of Excellence, Tehran, Iran

²Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran

³Pediatric Pulmonary Disease and Sleep Medicine Research Center, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran ⁴Division of Pediatric Intensive Care, Children's Medical Center, Tehran, Iran

^{*}Corresponding author: Division of Pediatric Intensive Care, Children's Medical Center, Tehran, Iran. Email: mmpour@tums.ac.ir

Received 2023 January 28; Revised 2023 January 31; Accepted 2023 January 31.

Keywords: Inflammatory, Pneumococcal Infections, Multiple Organ Involvement Syndrome, Children

Dear Editor,

Since early October 2022, we had to deal with some critically ill patients we had never dealt with. These cases were already identified in several cities in Iran and even in the world. The typical history of the majority of the cases was as follows: they were previously healthy children, mostly aged 1-10 years, and initially presented with flu-like symptoms such as fever, cough, and myalgia for 2-3 weeks before admission. After a transient recovery, symptoms flared up again. In the second phase of the illness, they experienced fever, general sense of ill-being, cough, and dyspnea. They were referred to several physicians' offices and received oral antibiotics and over-the-counter prescriptions. Finally, they sought medical attention due to worsening condition and were referred to our hospital. During the entire admission time, they were critically ill and had substantial respiratory distress.

They had variable degrees of lung involvement in chest imaging. An interesting finding was that a significant number of the cases had massive unilateral pleural effusion with or without empyema as well as white lung appearance in chest X-rays (CXR), which led to chest tube insertion and tissue plasminogen activator (tPA) administration in many cases. Most of them required intensive care, and some underwent intubation and mechanical ventilation. Vasoactive drugs were also prescribed for several patients. The clinical presentation had a rapid progressive nature, which we had not experienced in the pediatric population or even during the COVID-19 pandemic. The majority of these patients also had other organ involvements, especially increased cardiac biomarkers along with low systolic ejection fraction in favor of myocarditis, coagulopathy, and life-threatening bleeding, raised liver enzymes and acute hepatitis, and also increased level of creatinine with or without anuria resulting in dialysis. Otitis, adenitis, and meningitis were also observed in few cases. This multiorgan involvement was remarkably similar to what was already seen in multisystem inflammatory syndrome in children (MISC) following COVID-19 infection (1, 2).

Nasopharyngeal PCR for influenza, RSV, and COVID-19 viruses was checked in the course of laboratory investigation, and positive result was obtained for Influenza virus in few patients. The pleural fluid analysis showed considerable number of white blood count (WBC) and lactate dehydrogenase (LDH) in favor of exudative pattern. Another interesting finding was that pleural or blood cultures were positive in a great number of patients with Pneumococci or other organisms. Further evaluation revealed Streptococcus pneumoniae serotype 19-A in some samples, which is believed to cause invasive pneumococcal disease (3). On December 2022, World Health Organization (WHO), as well as the Centers for Disease Control and Prevention in the United States (CDC) also alarmed about an increase in invasive group A streptococcal infections with fatalities among children in Europe and United States (4, 5). On the other hand, some of our patients had high levels of ferritin and D-dimer; and despite appropriate antibiotic therapy, inflammatory markers and proper clinical response were not decreased. These findings along with multiorgan in-

Copyright © 2023, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

volvement highlighted the role of a post-infectious immune dysregulation rather than an isolated infectious process.

Unfortunately, two of these patients who had crucial cardiac involvement died during the studied period. Seemingly we faced a viral respiratory infection and possibly bacterial superinfection which triggered cytokine storm and resulted in multiple system involvement. Although administering initial treatment using antiviral or antibiotic drugs is inevitable when the symptoms of infection are present, anti-inflammatory treatment, including corticosteroids, should be considered early in the course of the disease, like inflammatory disorders seen in COVID-19 infection (6). To our experience, response to corticosteroid therapy was favorable and may have shortened the hospital length of stay.

In the final stages of our study, several patients and many challenges were left untreated and unresolved. Therefore, our research team continued collecting precise data about this unprecedented phenomenon, which would hopefully be published soon.

Acknowledgments

The authors would like to thank Professor Vahid Ziaei (Editor in chief) for his expert opinion and assistance throughout all stages of our study as well as for his valuable suggestions concerning writing this letter and developing the local guideline about this issue for our hospital, which will be published soon.

Footnotes

Authors' Contribution: M. O.: Drafting of the manuscript; M. Sh.: Study concept and design; S. H.

M: Acquisition of data; M. M.: Critical revision of the manuscript for important intellectual content

Conflict of Interests: The authors have no conflict of interests.

Funding/Support: It was not declared by the authors.

References

- Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management. *Children (Basel)*. 2020;7(7). [PubMed ID: 32630212]. [PubMed Central ID: PMC7401880]. https://doi.org/10.3390/children7070069.
- Guimaraes D, Pissarra R, Reis-Melo A, Guimaraes H. Multisystem inflammatory syndrome in children (MISC): A systematic review. Int J Clin Pract. 2021;75(11). e14450. [PubMed ID: 34105843]. https://doi.org/10.1111/jjcp.14450.
- Lai CY, Huang LM, Lee PY, Lu CY, Shao PL, Chang LY. Comparison of invasive pneumococcal disease caused by serotype 19A and non-19A pneumococci in children: more empyema in serotype 19A invasive pneumococcal disease. *J Microbiol Immunol Infect*. 2014;47(1):23-7. [PubMed ID: 23040234]. https://doi.org/10.1016/j.jmii.2012.08.011.
- 4. National Center for Immunization and Respiratory Diseases; Division of Bacterial Diseases. *Increase in Invasive Group A Strep Infections*, 2022–2023. Atlanta, USA: Centers for Disease Control and Prevention; 2023, [updated 2 Feb 2023; cited 25 Jan 2023]. Available from: https://www.cdc.gov/groupastrep/igas-infections-investigation.html#.
- World Health Organization. Increase in invasive Group A streptococcal infections among children in Europe, including fatalities. Geneva, Switzerland: World Health Organization; 2022, [updated 13 Dec 2022; cited 25 Jan 2023]. Available from: https://www.who.int/europe/news/item/12-12-2022-increasein-invasive-group-a-streptococcal-infections-among-children-ineurope--including-fatalities.
- Ziaee V, Assari R, Mamishi S, Zeinaloo A, Mohammadpour M, Malekzadeh I. An Algorithmic Approach to Multisystem Inflammatory Syndrome in Children with COVID-19: Tehran Children's Medical Center Protocol. *Iran J Pediatr.* 2020;**30**(5). https://doi.org/10.5812/ijp.108617.